GlobalData on MSN5d
Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patients
PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.
Monthly Prescribing Reference6d
Linerixibat Reduces Pruritus in Primary Biliary Cholangitis Trial
Treatment with liberixibat led to a statistically significant improvement in itch compared with placebo. Topline results were announced from a phase 3 trial evaluating linerixibat for the ...
London South East7d
GSK's linerixibat meets primary endpoint
(Sharecast News) - Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus in primary biliary cholangitis. GSK said the GLISTEN ...
Pharmabiz6d
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK plc announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter ...
London South East7d
GLISTEN Trial of Linerixibat Meets Endpoint
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) · Primary endpoint met with a statistically significant improvement in ...
Investing6d
GSK's phase III trial of linerixibat shows promise for PBC itch
GSK plc (LSE/NYSE: GSK) has announced positive results from its phase III GLISTEN trial of linerixibat, an investigational drug aimed at treating cholestatic pruritus (persistent itching ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...
Business Insider7d
GSK announces phase III trial of linerixibat met primary endpoint
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter ...
Investing6d
GSK's phase III trial of linerixibat shows promise for PBC itch
GSK plc (LSE/NYSE: LON:GSK) has announced positive results from its phase III GLISTEN trial of linerixibat, an investigational drug aimed at treating cholestatic pruritus (persistent itching) in ...